A Phase I Study of TheraCIM-hR3 (YMB1000) [nizotuzumab] in Patients With Solid Tumours

Trial Profile

A Phase I Study of TheraCIM-hR3 (YMB1000) [nizotuzumab] in Patients With Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2007

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors YM BioSciences
  • Most Recent Events

    • 20 Apr 2007 Status changed from recruiting to completed.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top